Relypsa (RLYP) Reports Q4 Loss of $0.80/Share

Relypsa (NASDAQ: RLYP) reported Q4 EPS of ($0.80), versus ($0.68) reported last year.

Financial Outlook

For the full year 2015, Relypsa expects operating expenses in the range of approximately $180.0 to $200.0 million, including stock-based compensation of approximately $10.0 to $15.0 million. The 2015 operating expenses will be primarily driven by ongoing development activities as we pursue regulatory approval of Patiromer FOS, expansion of commercial launch preparation activities related to Patiromer FOS, including significant headcount growth and the manufacture of commercial supply, and increases in our general and administrative infrastructure.

For earnings history and earnings-related data on Relypsa (RLYP) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• zSpace, Inc. (ZSPC) Reports Q2 results
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c